We choose indications by asking ourselves, “What problems are patients facing that need to be solved?”. Then, we use our scientific insights combined with our proprietary platform to highlight opportunities outside commonly-practiced approaches.
Spinal Muscular Atrophy and Other Myostatin-Related Disorders
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Apitegromab (SMA)
Next Anticipated Milestone: Enrollment of the Phase 3 SAPPHIRE Trial
The SAPPHIRE phase 3 study is initiated and will be evaluating apitegromab in patients with Non-Ambulatory Type 2 and 3 SMA.
Apitegromab (Myostatin-Related Disorders)
Myostatin-Related Disorders
Next Anticipated Milestone: Identify second indication for apitegromab
Target: Pro/Latent Myostatin
Description: Myostatin-Related Disorders
Oncology and Immuno-Oncology
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
SRK-181 (Context-Independent Latent TGFβ1) (Immuno-Oncology)
Immuno-Oncology (Primary resistance to checkpoint inhibitor therapies)
Next Anticipated Milestone: Advance progress in Part B of DRAGON Phase 1 Proof-of-Concept Trial
Target: TGFβ1
Description: Urothelial carcinoma, melanoma, non-small cell lung cancer, amongst other solid tumor types (primary resistance to checkpoint inhibitor therapies)
SRK-181 (Context Independent Latent TGFβ1) (Oncology)
Oncology
Target: TGFβ
Context-Dependent Latent TGFβ1 / Immune Cell (Oncology/Immuno-Oncology)
Oncology / Immuno-Oncology
Target: Latent TGFβ1
Context-Dependent Latent TGFβ1 / GARP (Oncology/Immuno-Oncology)
In partnership with Janssen
Oncology / Immuno-Oncology
Target: Latent TGFβ1
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Context-Independent Latent TGFβ1
Fibrosis
Target: Latent TGFβ1
Context-Dependent Latent TGFβ1 / LTBP1 & LTBP3
Fibrosis
Target: Latent TGFβ1 in association with LTBP-1 and -3
Iron-Restricted Anemias
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
BMP6 Signaling Pathway (anti-RGMc)
Iron-Restricted Anemias
Target: RGMc
Description: Iron-restricted
Clinical Trials
We focus on the discovery and development of safe and effective therapies to find optimal solutions for those who need it.
Partnerships
Help us shed light on the subject. Collaborate with us to uncover enlightened solutions for patients.